Dr. Reddy's Laboratories is currently trading at Rs. 2918.05, up by 19.00 points or 0.66% from its previous closing of Rs. 2899.05 on the BSE.
The scrip opened at Rs. 2900.00 and has touched a high and low of Rs. 2925.00 and Rs. 2898.10 respectively. So far 15427 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2803.50 on 16-Feb-2017.
Last one week high and low of the scrip stood at Rs. 2955.00 and Rs. 2803.50 respectively. The current market cap of the company is Rs. 48361.64 crore.
The promoters holding in the company stood at 26.79%, while institutions and non-institutions held 44.46% and 12.17% respectively.
Dr. Reddy’s Laboratories’ API manufacturing plant at Miryalaguda, has been audited by the US Food and Drug Administration (USFDA) and the audit has been completed on February 21, 2017. The company has been issued a Form 483 with three observations, which it is addressing.
Earlier, in January, South Korea’s Mezzion, a drug company was seeking damages from Dr. Reddy’s Laboratories in a New Jersey court for committing fraud by hiding significant deficiencies and misrepresenting compliance in its manufacturing practices. The suit stated that Dr. Reddy’s repeatedly represented to Mezzion that it was compliant with FDA regulations, and that it hid its misconduct from Mezzion.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.